OKYO Pharma Limited (OKYO)

1.1600 -0.0500 (-4.13%) At close: 04:00PM EDT

OKYO Pharma Limited

14/15 Conduit St
Floor 4
London W1S 2XJ
United Kingdom
44 20 7495 2379
https://www.okyopharma.com

Sector(s): Healthcare
Industry: Biotechnology
Full Time Employees: 8

Key Executives

Name	Title	Pay	Exercised	Year Born
Dr. Gary S. Jacob Ph.D.	CEO & Executive Director	650k	N/A	1947
Mr. Michael Paul Beck	Founder	N/A	N/A	1957
Ms. Keeren Shah	Chief Financial Officer	N/A	N/A	1976
Dr. William A. Clementi Ph.D., Pharm.D.	Chief Operating Officer	N/A	N/A	N/A
Dr. Rajkumar Patil Ph.D.	Chief Scientific Officer	N/A	N/A	1959

Amounts are as of December 31, 2023 and compensation values are for the last fiscal year ending on that date. Pay is salary, bonuses, etc. Exercised is the value of options exercised during the fiscal year. Currency in USD.

Description

OKYO Pharma Limited, a clinical-stage biopharmaceutical company, engages in developing therapeutics for patients suffering from inflammatory eye diseases and ocular pain in the United Kingdom. Its lead preclinical product candidate is OK-101, which is in Phase II clinical trials for the treatment of dry eye disease. The company is also developing OK-201, a bovine adrenal medulla, lipidated-peptide preclinical analogue candidate for the treatment of neuropathic chronic pain. The company was incorporated in 2007 and is headquartered in London, the United Kingdom.

Corporate Governance

OKYO Pharma Limited’s ISS Governance QualityScore as of N/A is N/A. The pillar scores are Audit: N/A; Board: N/A; Shareholder Rights: N/A; Compensation: N/A.

Corporate governance scores courtesy of Institutional Shareholder Services (ISS). Scores indicate decile rank relative to index or region. A decile score of 1 indicates lower governance risk, while a 10 indicates higher governance risk.